GlaxoSmithKline Pharmaceuticals Ltd on Wednesday reported a consolidated net profit from continuing operations at Rs 133.43 crore in the fourth quarter ended March 2023.
The company had posted a consolidated net loss from continuing operations at Rs 54.66 crore a year ago, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing.
Its consolidated revenue from continuing operations stood at Rs 787.45 crore against Rs 809.63 crore in the year-ago period.
The total expenses in the quarter were higher at Rs 635.54 crore compared to Rs 650.04 crore in the corresponding period of the previous year.
For FY23, consolidated net profit from continuing operations was Rs 607.64 crore against Rs 380.77 crore in FY22.
The company said its consolidated revenue from continuing operations stood at Rs 3,251.72 crore in FY23 compared to Rs 3,278.03 crore in FY22.
Also Read
General medicine portfolio saw double-digit underlying growth and the company continued to maintain market leadership in therapies, such as dermatology and pain, GSK Pharma said, adding the self-pay vaccines market continued to decline year-on-year with early signs of recovery.
"GSK remains focused on gaining share and defending the leadership position of key brands for therapies in which we operate. With the launch of our global blockbuster Shingrix we expect to address an unmet preventive health need and gain momentum for our vaccines business," GSK Pharma Managing Director Bhushan Akshikar said.
The company said its Board has recommended a dividend of Rs 32 per equity share on the face value of Rs 10 each for the year ended March 31, 2023, subject to the approval of members at its ensuing 98th annual general meeting.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
